Clinical Trial Search

Primary: Percentage of Patients Achieving Clinical Remission (Based on CDAI) at Week 54 — 144; 36 Participants — p=<0.0001

Primary: Percentage of Participants With Mucosal Healing and No Deep Ulcerations — 30.3; 45.9 percentage of participants — p=0.010

Primary: Percentage of Participants Achieving Endoscopic Remission at Week 26 — 34.5 percentage of participants

Primary: Percentage of Participants With Active CD at Day 1 — 45.3 percentage of participants

Primary: Remission After 8-week of Treatment — 17; 14 Participants — p=0.526

Primary: Percentage of Participants With Crohn's Disease Activity Index (CDAI) 70 Response Rate — 52.7; 60.1; 62.7; 47.7 Percentage of Participants — p=0.3393

Primary: Change in Disease Activity by Harvey Bradshaw Index — -5; -3 score on a scale

Primary: Safety and Tolerability of Ciprofloxacin — 25; 11; 9; 1 Adverse events

Primary: Percentage of Participants That Achieved Symptomatic Remission at Week 6 — 40; 46 Participants

Primary: Sustained Relapse-free Remission — 6; 5 Participants

Primary: Part I: Change From Baseline in the Crohn's Disease Activity Index (CDAI) Score at Week 8 — -60.0; -103.6 units on a scale

Primary: Prevalence of Inflammation as Diagnosed by Capsule Endoscopy — 6 participants

Primary: Number of Participants With Moderate to Severe UC Who Showed Clinical Remission as Defined by the MMS — 9; 17; 22 Participants

Primary: Change Lewis Score Index — -225 units on a scale

Primary: Percentage of Participants Who Achieve Endoscopic Remission at Week 12/16 — 0; 10.3; 8.1; 8.3 percentage of participants — p=0.056

Primary: Induction Phase: Cohort 1: Percentage of Participants With Clinical Remission at Week 14 — 11.9; 20.00; 27.3 Percentage of Particiapnts

Primary: Endoscopic Recurrence: the Proportion of Patients in Endoscopic Recurrence at One Year — 1; 11 participants — p=.0005

Primary: Mucosal Change in VCE (Video Capsule Endoscopy) Mucosal Scores and PGA (Physician Global Assessment) — -0.3; -382.9; -2.7 units on a scale — p=0.631

Primary: Number of Subjects Without Mucosal Ulceration at Week 12 — 8; 17 Subjects — p=0.056

Primary: Number of Participants With Clinical Remission for Crohn's Disease — 6 Participants

Primary: Number of Participants With Clinical Response at Week 6 — 31; 48; 45; 52 Participants — p=0.005

Primary: Cost of Illness in Participants With Crohn's Disease — 6088.40; 6169.62; 5594.00; 5825.80 Euros

Primary: Change in FCP in Group 2 Participants — 1501 mcg/g — p=1.0

Primary: Number of Participants in Clinical Remission at Treatment Week 20. Clinical Remission Defined as Harvey Bradshaw Index (HBI) Score Less Than 5. — 492 Participants

Primary: Percentage of Participants in Clinical Remission in the Tumor Necrosis Factor Alpha (TNFα) Antagonist Failure Subpopulation — 12.1; 15.2 percentage of participants…

Primary: Percentage of Participants Who Achieved Clinical Remission at Week 4 — 43.7; 43.5 percentage of participants — p=0.939

Primary: Number of Participants With Clinical Response 70 at Week 4 — 14; 13; 18; 16 participants

Primary: Number of Participants With MRI Positivity- Global Assessment Positive — 4; 0 Participants

Primary: Mean Extent of Exposure - Duration in Days — 159.2 days

Primary: Percentage of Participants With Remission at Week 8 — 13.3; 23.1; 14.3; 19.5 percentage of participants — p=0.76